全文获取类型
收费全文 | 111350篇 |
免费 | 8564篇 |
国内免费 | 368篇 |
专业分类
耳鼻咽喉 | 1181篇 |
儿科学 | 2928篇 |
妇产科学 | 2141篇 |
基础医学 | 14294篇 |
口腔科学 | 1890篇 |
临床医学 | 11612篇 |
内科学 | 21946篇 |
皮肤病学 | 1499篇 |
神经病学 | 10176篇 |
特种医学 | 4062篇 |
外国民族医学 | 4篇 |
外科学 | 18857篇 |
综合类 | 1560篇 |
现状与发展 | 1篇 |
一般理论 | 125篇 |
预防医学 | 10462篇 |
眼科学 | 2413篇 |
药学 | 7461篇 |
1篇 | |
中国医学 | 115篇 |
肿瘤学 | 7554篇 |
出版年
2023年 | 486篇 |
2021年 | 2061篇 |
2020年 | 1197篇 |
2019年 | 2002篇 |
2018年 | 2430篇 |
2017年 | 1724篇 |
2016年 | 1891篇 |
2015年 | 2207篇 |
2014年 | 3392篇 |
2013年 | 4886篇 |
2012年 | 7276篇 |
2011年 | 7665篇 |
2010年 | 4249篇 |
2009年 | 3841篇 |
2008年 | 6805篇 |
2007年 | 7228篇 |
2006年 | 7069篇 |
2005年 | 7100篇 |
2004年 | 6767篇 |
2003年 | 6291篇 |
2002年 | 6051篇 |
2001年 | 1349篇 |
2000年 | 1191篇 |
1999年 | 1391篇 |
1998年 | 1375篇 |
1997年 | 1121篇 |
1996年 | 840篇 |
1995年 | 1015篇 |
1994年 | 887篇 |
1993年 | 817篇 |
1992年 | 884篇 |
1991年 | 843篇 |
1990年 | 789篇 |
1989年 | 763篇 |
1988年 | 703篇 |
1987年 | 639篇 |
1986年 | 626篇 |
1985年 | 724篇 |
1984年 | 817篇 |
1983年 | 687篇 |
1982年 | 760篇 |
1981年 | 717篇 |
1980年 | 680篇 |
1979年 | 480篇 |
1978年 | 513篇 |
1977年 | 447篇 |
1976年 | 389篇 |
1975年 | 379篇 |
1974年 | 437篇 |
1973年 | 362篇 |
排序方式: 共有10000条查询结果,搜索用时 18 毫秒
1.
Qian Zhang Larry D. Mesner Gina M. Calabrese Naomi Dirckx Zhu Li Angela Verardo Qian Yang Robert J. Tower Marie-Claude Faugere Charles R. Farber Thomas L. Clemens 《The Journal of clinical investigation》2021,131(7)
Bone mineral density (BMD) is a highly heritable predictor of osteoporotic fracture. GWAS have identified hundreds of loci influencing BMD, but few have been functionally analyzed. In this study, we show that SNPs within a BMD locus on chromosome 14q32.32 alter splicing and expression of PAR-1a/microtubule affinity regulating kinase 3 (MARK3), a conserved serine/threonine kinase known to regulate bioenergetics, cell division, and polarity. Mice lacking Mark3 either globally or selectively in osteoblasts have increased bone mass at maturity. RNA profiling from Mark3-deficient osteoblasts suggested changes in the expression of components of the Notch signaling pathway. Mark3-deficient osteoblasts exhibited greater matrix mineralization compared with controls that was accompanied by reduced Jag1/Hes1 expression and diminished downstream JNK signaling. Overexpression of Jag1 in Mark3-deficient osteoblasts both in vitro and in vivo normalized mineralization capacity and bone mass, respectively. Together, these findings reveal a mechanism whereby genetically regulated alterations in Mark3 expression perturb cell signaling in osteoblasts to influence bone mass. 相似文献
2.
3.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
4.
5.
6.
Kenny P. Pang FRCSEd FRCSI Claudio Vicini MD Filippo Montevecchi MD Ottavio Piccin MD MSc Sudipta Chandra MBBS MS Hyung C. Yang MD PhD Vikas Agrawal MS DLO Joseph C. K. Chung FRCS Yiong H. Chan BSc PhD Scott B. Pang Kathleen A. Pang Edward B. Pang Brian Rotenberg MD MPH FRCSC 《The Laryngoscope》2020,130(9):2281-2284
7.
8.
9.
Michelle E. Wilson Charles Kim Jacqueline Carrasco 《Orbit (Amsterdam, Netherlands)》2016,35(5):288-291
A 48-year-old smoker with a history of hyperthyroidism treated 10 years prior to presentation with radioactive iodine ablation of the thyroid gland presented to his ophthalmologist with a 2-week history of transient loss of vision in the right eye occurring for 1 to 2 hours each morning. He denied ocular pain, diplopia or change in the prominence of one or both eyes. Examination revealed 2 mm of relative proptosis on the right, bilateral temporal flare and lower lid retraction. There was minimal upper lid retraction and no evidence of lid lag. Ocular motility was full. Dilated fundoscopic examination revealed bilateral optic nerve edema, right more than left. CT of the orbit demonstrated enlargement of the extraocular muscles bilaterally with marked enlargement of the right medial rectus and left inferior rectus muscles resulting in crowding at the orbital apex bilaterally. Laboratory testing revealed the patient to be hyperthyroid. The patient was treated with high dose oral steroids followed by orbital radiation. Hyperthyroidism was managed by the patient’s primary care physician. Visual symptoms rapidly improved with oral steroids and orbital radiation. Optic nerve edema completely resolved. Repeat CT imaging demonstrated a reduction in the enlargement of the extraocular muscles with relief of bilateral optic nerve compression. 相似文献
10.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献